Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later, irreversible stage of platelet aggregation. Without intervention, events leading to pathological platelet activation can result in vessel occlusion, acute coronary syndrome, and stroke. Therefore, a better understanding of events leading to platelet-mediated clot formation may provide insight into new therapeutic targets. Once activated, protease activated receptors (PARs) are essential in regulating events leading to platelet aggregation. We have determined a signaling cascade through PAR1, which involves phosphatidylinositol (PI) kinases, phosphatidylinositol bisphosphate (PIP 2 ), and Rap1 activation (independent of P2Y12) in the formation of a stable platelet aggregate. The putative phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 was found to reduce basal and PAR-stimulated PIP 2 levels by mass spectrometry and to inhibit PAR1-mediated stable platelet aggregation. Rap1 activation in platelets (during time points corresponding to the late, irreversible phase of aggregation) was found to require the PI signaling pathway. Perturbation of PI3K signaling by isoform-selective inhibitors had differential effects on Rap1 activation through PAR1 and PAR4. Hence, it is possible to disrupt lipid signaling pathways involved in stable clot formation without inhibiting early clot formation, offering a new potential target for antiplatelet therapy.Research spanning nearly three decades has firmly established the role of platelet activation in the pathophysiology of cardiovascular disease and acute coronary syndromes (Elwood et al., 1991;Ross, 1999;Gurbel and Bliden, 2003), because platelet activation plays a critical role in the formation of intravascular thrombus at the site of arterial injury or plaque rupture (Fuster et al., 1992). Under pathological conditions, a local increase in thrombin concentrations may result in a perpetual feed-forward activation of platelets, resulting in subsequent occlusion of coronary vessels and stroke. In platelets, thrombin signals through the activation of protease-activated receptors (PAR1 and PAR4). Inhibition of specific points in PAR signaling pathways leads to the attenuation of normal aggregation kinetics , suggesting that regulation of PAR1-and PAR4-mediated aggregation does not occur through identical signaling cascades.Phosphatidylinositol phosphates PIP, PIP 2 , and PIP 3 (PIP n ) are produced upon the activation of PI-kinases. In human platelets, PI(4,5)P 2 (PIP 2 ) is the major substrate for PI(3,4,5)P 3 , (PIP 3 ) and both of these have been implicated in thrombin-mediated signaling processes in platelets (Hartwig et al., 1995;Yang et al., 2004). A number of studies have investigated the role of PI3-kinase (PI3K)  in outside-in signaling, and studies suggest a potential role for other PI3K isoforms in inside-out signaling (Jackson et al